Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04261075
Title IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

Advanced Solid Tumor

Therapies

Durvalumab + IPH5201 + Oleclumab

Durvalumab + IPH5201

IPH5201

Age Groups: adult | senior
Covered Countries USA | FRA | ESP

Facility Status City State Zip Country Details
Research Site Huntersville North Carolina 28078 United States Details
Research Site Providence Rhode Island 02906 United States Details
Research Site Nashville Tennessee 37203 United States Details
Research Site Bordeaux Cedex 33076 France Details
Research Site Villejuif 94805 France Details
Research Site Barcelona 8035 Spain Details
Research Site Madrid 28027 Spain Details
Research Site Lausanne 1011 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field